Articles from Quiver Bioscience

Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders and chronic pain, today announced receipt of a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The Phase II grant, awarded by the National Institute of Neurological Disease and Stroke (NINDS) is titled “Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity.” It will provide Quiver with $2.15 million over three years to continue development of an integrated platform for improved prediction of safety and tolerability of CNS-targeted antisense oligonucleotide (ASO) therapeutics.

Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders and chronic pain, announced the appointment of co-founder Graham Dempsey, PhD as Chief Executive Officer. Dr. Dempsey assumes the CEO role after more than a decade of scientific and operational leadership at Quiver, most recently serving as Quiver’s Chief Scientific Officer, directing the planning and execution of all scientific, medical, engineering and AI/machine learning activities at the company. This appointment comes as Quiver aims to advance its lead program into the clinic, an antisense oligonucleotide (ASO) targeting Nav1.7 for the treatment of chronic pain, while scaling its CNS-focused AI-driven drug discovery platform to accelerate a portfolio of therapeutic programs. Paul Roma, Quiver co-founder and interim CEO will transition to Chairman of the Board of Directors.

Quiver Bioscience (“Quiver”) and QurAlis Corporation (“QurAlis”), today announced that the companies have entered into a research collaboration to advance a novel gene-targeted therapeutic approach for the treatment of Fragile X syndrome (FXS). The goal of the collaboration is to combine Quiver’s unique “Genomic Positioning System” (GPS) drug discovery platform with QurAlis’ expertise in developing next-generation precision medicines for neurodegenerative and neurological diseases to build a foundational data package in support of advancing a potentially transformative therapeutic for FXS.

Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of serious central nervous system (CNS) disorders, announces today a collaboration with the Dup15q Alliance to advance an antisense oligonucleotide (ASO) therapeutic program for chromosome 15q duplication (Dup15q) syndrome using Quiver’s innovative “Genomic Positioning System” (GPS). There are currently no disease-modifying treatments for Dup15q, which remains a substantial unmet medical need.

Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders, announces a peer-reviewed publication in Nature Communications Biology. The paper, titled “Deep functional measurements of Fragile X syndrome human neurons reveal multiparametric electrophysiological disease phenotype” features application of Quiver’s ‘Genomic Positioning System (GPS)’ platform to develop a robust human neuronal model of Fragile X Syndrome (FXS) and enable drug discovery efforts for the neurodevelopmental disorder. Quiver’s GPS platform, on full display in the study, integrates unique-in-world, scalable, human neuronal electrophysiology data (the ‘language’ of the brain) with artificial intelligence and machine learning (AI/ML) to drive novel insights into the best therapeutics for the right patients.